SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Kauffman CA, Nicolasora NP. Epidemiology of invasive pulmonary aspergillosis. In: Pasqualotto AC (ed.) Aspergillosis: From Diagnosis to Prevention. Springer, New York, 2009; 32944.
  • 2
    Pasqualotto AC. Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus. Med. Mycol. 2009; 47: S26170.
  • 3
    van der Linden JWM, Warris A, Verweij PE. Aspergillus species intrinsically resistant to antifungal agents. Med. Mycol. 2011; 49: S829.
  • 4
    Cramer RA, Rivera A, Hohl T. Immune responses against Aspergillus fumigatus: what have we learned? Curr. Opin. Infect. Dis. 2011; 24: 31522.
  • 5
    Singh N, Husain S. AST Infectious Diseases Community of Practice. Invasive aspergillosis in solid organ transplant recipients. Am. J. Transplant. 2009; 9(Suppl. 4): S18091.
  • 6
    Ben-Ami R, Lewis R, Kontoyiannis DP. Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges. Curr. Opin. Infect. Dis. 2009; 22: 37684.
  • 7
    Georgiadou SP, Sipsas NV, Marom EM et al. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin. Infect. Dis. 2011; 52: 114455.
  • 8
    Park SY, Kim SH, Choi SH et al. Clinical and radiological features of invasive pulmonary aspergillosis in transplant recipients and neutropenic patients. Transpl. Infect. Dis. 2010; 12: 30915.
  • 9
    Segal BH. Aspergillosis. N. Engl. J. Med. 2009; 360: 187084.
  • 10
    De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 2008; 46: 181321.
  • 11
    Maertens J, Theunissen K, Lodewyck T et al. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses 2007; 50 (Suppl. 1): 217.
  • 12
    Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin. Infect. Dis. 2006; 42: 141727.
  • 13
    Miceli MH, Grazziutti ML, Woods G et al. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin. Infect. Dis. 2008; 46: 141222.
  • 14
    Husain S, Kwak EJ, Obman A et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am. J. Transplant. 2004; 4: 796802.
  • 15
    Clancy CJ, Jaber RA, Leather HL et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J. Clin. Microbiol. 2007; 45: 175965.
  • 16
    Husain S, Clancy CJ, Nguyen MH et al. Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid. Clin. Vaccine Immunol. 2008; 15: 17603.
  • 17
    Guo YL, Chen YQ, Wang K et al. Accuracy of bronchoalveolar lavage galactomannan in diagnosing invasive aspergillosis: a bivariate meta-analysis and systematic review. Chest 2010; 138: 81724.
  • 18
    Maertens J, Maertens V, Theunissen K et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin. Infect. Dis. 2009; 49: 168893.
  • 19
    Mengoli C, Cruciani M, Barnes RA et al. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect. Dis. 2009; 9: 8996.
  • 20
    White LP, Perry MD, Moody A et al. Evaluation of analytical and preliminary clinical performance of Myconostica MycAssay Aspergillus when testing serum specimens for diagnosis of invasive aspergillosis. J. Clin. Microbiol. 2011; 49: 216974.
  • 21
    Luong M-L, Clancy CJ, Vadnerkar A et al. Comparison of an Aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. Clin. Infect. Dis. 2011; 52: 121826.
  • 22
    Torelli R, Sanguinetti M, Moody A et al. Diagnosis of invasive aspergillosis by a commercial real-time PCR assay for Aspergillus DNA in bronchoalveolar lavage fluid samples from high-risk patients compared to a galactomannan assay. J. Clin. Microbiol. 2011; 49: 427378.
  • 23
    Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 2002; 347: 40815.
  • 24
    Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 2008; 46: 32760.
  • 25
    Limper AH, Knox KS, Sarosi GA et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am. J. Respir. Crit. Care Med. 2011; 183: 96128.
  • 26
    Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 2007; 44: 212.
  • 27
    Verweij PE, Snelders E, Kema GHJ et al. Azole resistance in Aspergillus fumigatus: a side effect of environmental fungicide use. Lancet Infect. Dis. 2009; 9: 78995.
  • 28
    Howard SJ, Arendrup MC. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med. Mycol. 2011; 49: S905.
  • 29
    Bowyer P, Moore CB, Rautemaa R et al. Azole antifungal resistance today: focus on aspergillosis. Curr. Infect. Dis. Rep. 2011; 13: 48591.
  • 30
    van der Linden JWM, Snelders E, Kampinga GA et al. Clinical implications of azole resistance in Aspergillus fumigatus, the Netherlands, 2007-2009. Emerg. Infect. Dis. 2011; 17: 184654.
  • 31
    Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin. Infect. Dis. 2010; 50: 1091100.
  • 32
    Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 2005; 41: 63453.
  • 33
    Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J. Infect. Dis. 2005; 191: 135060.
  • 34
    Trifilio S, Singhal S, Williams S et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 2007; 40: 4516.
  • 35
    Chamilos G, Marom EM, Lewis RE et al. Predictors of pulmonary zygomycosis versus invasive aspergillosis in patients with cancer. Clin. Infect. Dis. 2005; 41: 606.
  • 36
    Hammond SP, Baden LR, Marty FM. Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob. Agents Chemother. 2011; 55: 501821.
  • 37
    Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin. Infect. Dis. 2008; 47: 5039.
  • 38
    Ibrahim AS, Edwards JE Jr, Filler SG et al. Mucormycosis and entomophthoramycosis (zygomycosis). In: Kauffman CA, Pappas PG, Sobel JD et al. (eds) Essentials of Clinical Mycology, 2nd edn. Springer, New York, 2011; 26580.
  • 39
    Bialek R, Konrad F, Kern J et al. PCR-based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. J. Clin. Pathol. 2005; 58: 11804.
  • 40
    Hammond SP, Bialek R, Milner DA et al. Molecular methods to improve the diagnosis and identification of mucormycosis. J. Clin. Microbiol. 2011; 49: 21513.
  • 41
    Kontoyiannis DP, Lewis R. How I treat mucormycosis. Blood 2011; 118: 121624.
  • 42
    Lewis RE, Albert ND, Liao G et al. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob. Agents Chemother. 2010; 54: 1298304.
  • 43
    Torres HA, Hachem RY, Chemaly RF et al. Posaconazole: a broad spectrum triazole agent. Lancet Infect. Dis. 2005; 5: 77585.
  • 44
    Spellberg B, Walsh TJ, Kontoyiannis DP et al. Recent advances in the management of mucormycosis: from bench to bedside. Clin. Infect. Dis. 2009; 48: 174351.
  • 45
    Torres HA, Kontoyiannis DP. Hyalohyphomycoses (hyaline molds). In: Kauffman CA, Pappas PG, Sobel JD et al. (eds) Essentials of Clinical Mycology, 2nd edn. Springer, New York, 2011; 281304.
  • 46
    Gilgado F, Cano J, Gené J et al. Different virulence of the species of the Pseudallescheria boydii complex. Med. Mycol. 2009; 47: 3714.
  • 47
    Rodriquez-Tudela JL, Berenguer J, Guarro J et al. Epidemiology and outcome of Scedosporium prolificans infection: a review of 162 cases. Med. Mycol. 2009; 47: 35970.
  • 48
    Husain S, Alexander B, Munoz P et al. Opportunistic mycelial fungi in organ transplant recipients: emerging importance of non-Aspergillus mycelial infections. Clin. Infect. Dis. 2003; 37: 2219.
  • 49
    Nucci M, Marr KA, Queiroz-Telles F et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 2004; 38: 123742.
  • 50
    Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin. Microbiol. Rev. 2007; 20: 697704.
  • 51
    Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin. Infect. Dis. 2002; 35: 90920.
  • 52
    Castelli MV, Buitrago MJ, Bernal-Martinez L et al. Development and validation of a quantitative PCR assay for diagnosis of scedosporiosis. J. Clin. Microbiol. 2008; 46: 34126.
  • 53
    Hayden RT, Isotalo PA, Parrett T et al. In situ hybridization for the differentiation of Aspergillus, Fusarium, and Pseudallescheria species in tissue section. Diagn. Mol. Pathol. 2003; 12: 216.
  • 54
    Lortholary O, Obenga G, Biswas P et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob. Agents Chemother. 2010; 54: 444650.
  • 55
    Raad II, Hachem RY, Herbrecht R et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 2006; 42: 1398403.
  • 56
    Ho DY, Lee JD, Rosso F et al. Treating disseminated fusariosis: amphotericin B, voriconazole, or both? Mycoses 2007; 50: 22731.
  • 57
    Troke P, Aguirrebengoa K, Arteaga C et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob. Agents Chemother. 2008; 52: 174350.
  • 58
    Steinbach WJ, Perfect JR. Scedosporium species infections and treatments. J. Chemother. 2003; 15: 1627.
  • 59
    Harris JR, Lockhart SR, Debess E et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin. Infect. Dis. 2011; 53: 118895.
  • 60
    Pappas PG, Perfect JR, Cloud GA et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin. Infect. Dis. 2001; 33: 6909.
  • 61
    Singh N, Dromer F, Perfect JR et al. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin. Infect. Dis. 2011; 47: 13217.
  • 62
    Chang WC, Tzao C, Hsu HH et al. Pulmonary cryptococcosis: comparison of clinical and radiographic characteristics in immunocompetent and immunocompromised patients. Chest 2006; 129: 33340.
  • 63
    Baddley JW, Perfect JR, Oster RA et al. Pulmonary cryptococcosis in patients without HV infection: factors associated with disseminated disease. Eur. J. Clin. Microbiol. Infect. Dis. 2008; 27: 93743.
  • 64
    Singh N, Forrest G, Infectious AST. Diseases Community of Practice. Cryptococcosis in solid organ transplant recipients. Am. J. Transplant. 2009; 9(Suppl. 4): S1928.
  • 65
    Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2010; 50: 291322.
  • 66
    Saccente M, Woods GL. Clinical and laboratory update on blastomycosis. Clin. Microbiol. Rev. 2010; 23: 36781.
  • 67
    Smith JA, Kauffman CA. Blastomycosis. Proc. Am. Thorac. Soc. 2010; 7: 17380.
  • 68
    Lemos LB, Baliga M, Guo M. Acute respiratory distress syndrome and blastomycosis: presentation of nine cases and review of the literature. Ann. Diagn. Pathol. 2001; 5: 19.
  • 69
    Martynowicz MA, Prakash UB. Pulmonary blastomycosis: an appraisal of diagnostic techniques. Chest 2002; 121: 76873.
  • 70
    Durkin M, Witt J, Lemonte A et al. Antigen assay with the potential to aid in diagnosis of blastomycosis. J. Clin. Microbiol. 2004; 42: 48735.
  • 71
    Bariola JR, Hage CA, Durkin M et al. Detection of Blastomyces dermatitidis antigen in patients with newly diagnosed blastomycosis. Diagn. Microbiol. Infect. Dis. 2011; 69: 18791.
  • 72
    Carlos WG, Rose AS, Wheat LJ et al. Blastomycosis in Indiana: digging up more cases. Chest 2010; 138: 137782.
  • 73
    Babady NE, Buckwalter SP, Hall L et al. Detection of Blastomyces dermatitidis and Histoplasma capsulatum from culture isolates and clinical specimens by use of real-time PCR. J. Clin. Microbiol. 2011; 49: 32048.
  • 74
    Chapman SW, Dismukes WE, Proia LA et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2008; 46: 180112.
  • 75
    Lahm T, Neese S, Thornburg AT et al. Corticosteroids for blastomycosis-induced ARDS; a report of two patients and review of the literature. Chest 2008; 133: 147880.
  • 76
    Kauffman CA. Histoplasmosis: clinical and laboratory update. Clin. Microbiol. Rev. 2007; 20: 11532.
  • 77
    Wheat LJ, Conces D, Allen SD et al. Pulmonary histoplasmosis syndromes: recognition, diagnosis, and management. Sem. Respir. Crit. Care Med. 2004; 25: 12944.
  • 78
    Wheat LJ. Approach to the diagnosis of the endemic mycoses. Clin. Chest Med. 2009; 30: 37989.
  • 79
    Swartzentruber S, Rhodes L, Kurkjian K et al. Diagnosis of acute pulmonary histoplasmosis by antigen detection. Clin. Infect. Dis. 2009; 49: 187882.
  • 80
    Hage CA, Davis TE, Fuller D et al. Diagnosis of histoplasmosis by antigen detection in BAL fluid. Chest 2010; 137: 6238.
  • 81
    Hage CA, Ribes JA, Wengenack NL et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin. Infect. Dis. 2011; 53: 44854.
  • 82
    Wheat LJ, Freifeld AG, Kleiman MB et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2007; 45: 80725.
  • 83
    Freifeld A, Proia L, Andes D et al. Voriconazole use for endemic fungal infections. Antimicrob. Agents Chemother. 2009; 53: 164851.
  • 84
    Doyle TP, Loyd JE, Robbins IM. Percutaneous pulmonary artery and vein stenting: a novel treatment for mediastinal fibrosis. Am. J. Respir. Crit. Care Med. 2001; 164: 65760.
  • 85
    Ampel NM. Coccidioidomycosis. In: Kauffman CA, Pappas PG, Sobel JD et al. (eds) Essentials of Clinical Mycology, 2nd edn. Springer, New York, 2011; 34966.
  • 86
    Anstead GM, Graybill JR. Coccidioidomycosis. Infect. Dis. Clin. North Am. 2006; 20: 62143.
  • 87
    Pappagianis D. Current status of serologic studies in coccidioidomycosis. Curr. Fungal Infect. Rep. 2007; 1: 12934.
  • 88
    Durkin M, Connolly P, Kuberski T et al. Diagnosis of coccidioidomycosis with use of the Coccidioides antigen enzyme immunoassay. Clin. Infect. Dis. 2008; 47: e6973.
  • 89
    Galgiani JN, Ampel NM, Blair JE et al. Coccidioidomycosis. Clin. Infect. Dis. 2005; 41: 121723.
  • 90
    Kim MM, Vikram HR, Kusne S et al. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin. Infect. Dis. 2011; 53: 10606.